Introduction

Despite substantial advances in breast cancer diagnosis and treatment, recurrence remains a major clinical concern. Standard therapeutic modalities—including surgery, chemotherapy, radiation therapy, endocrine therapy, and targeted biologics—have significantly improved survival rates, yet they do not eliminate the risk of relapse. Recurrence may occur locally, regionally, or at distant metastatic sites, sometimes many years after apparent remission. Depending on subtype and stage, recurrence rates may range from approximately 25% to 40%.

A growing body of evidence suggests that disease recurrence may be driven, at least in part, by a small but biologically significant population of cells known as cancer stem cells (CSCs). Increasingly, these cells are being recognized as critical contributors to therapeutic resistance, metastatic progression, and tumor re-initiation.

Breast Cancer Stem Cells and Their Clinical Significance

Cancer stem cells are a subpopulation of malignant cells possessing the capacity for self-renewal, differentiation, and tumor regeneration. Unlike the bulk of tumor cells—which often respond to cytotoxic treatment—CSCs may remain quiescent, evade conventional therapies, and survive within protective tumor microenvironments. In breast cancer, breast cancer stem cells (BCSCs) have been associated with resistance to chemotherapy and radiation, tumor regrowth following treatment, metastatic dissemination, and poorer long-term prognosis.

BCSCs are commonly identified by markers such as CD44⁺/CD24⁻ and ALDH1 positivity and exhibit activation of developmental pathways including Wnt/β-catenin, Notch, and Hedgehog, which regulate stemness, proliferation, and survival. Because these signaling pathways overlap with those of normal stem cells, pharmacologic targeting of BCSCs remains a significant therapeutic challenge.

Botanical Compounds and Selective Anti-Cancer Activity

Interest in plant-derived compounds capable of selectively targeting malignant cells while minimizing systemic toxicity has grown considerably within integrative oncology. Among the compounds under investigation are extracts originally identified through the work of French molecular biologist Dr. Mirko Beljanski, whose research focused on the destabilization of DNA by environmental carcinogens and the identification of natural compounds with selective affinity for altered DNA conformations.

Subsequent university-based research supported by The Beljanski Foundation has investigated two botanical extracts in particular: Pao pereira (Geissospermum vellosii) and reserpine-free Rauwolfia vomitoria.

Preclinical Evidence in Solid Tumor Models

Studies conducted at Kansas University Medical Center (KUMC) have demonstrated anti-tumor activity of these extracts in multiple cancer models. Published findings have shown inhibition of ovarian cancer growth and potentiation of carboplatin efficacy, as well as inhibition of pancreatic tumor growth and enhancement of gemcitabine efficacy.^5,8 In these models, the extracts induced apoptosis and suppressed proliferation in malignant cells.

Independent investigators have further shown that flavopereirine, a principal alkaloid of Pao pereira, inhibits proliferation and induces apoptosis in human breast cancer cells through modulation of the AKT/p38 MAPK/ERK signaling pathway.^9,10

Effects on Cancer Stem Cells

Particularly noteworthy are more recent studies demonstrating inhibition of pancreatic cancer stem cells by both Pao pereira and Rauwolfia vomitoria extracts. Investigators reported suppression of tumorsphere formation and disruption of Wnt/β-catenin signaling, a key pathway involved in CSC self-renewal.^11,12 These findings suggest that certain botanical compounds may target not only differentiated tumor cells but also the stem-like subpopulation responsible for recurrence and metastasis.

Building on these data, ongoing preclinical work is evaluating the effects of combinations including Pao pereira, Rauwolfia vomitoria, green tea catechins, and golden leaf Ginkgo biloba extract on breast cancer stem cell signaling and metastatic behavior.

Preliminary Findings in Breast Cancer Models

Preliminary data presented at the 2025 Beljanski Integrative Cancer Conference demonstrated significant anti-metastatic effects in a murine model of human breast cancer treated with these botanical combinations. According to the investigators, none of the treated animals developed metastases, whereas metastatic progression occurred in many untreated controls. Secondary tumor formation was likewise significantly reduced in treated animals. These findings remain preliminary pending peer-reviewed publication; however, they suggest possible suppression of stem cell-driven metastatic mechanisms.

Clinical Implications for Integrative Oncology

If future translational and clinical studies confirm the ability of botanical interventions to suppress breast cancer stem cells safely and effectively, such compounds may eventually serve as valuable adjuncts in recurrence prevention strategies and survivorship care. This emerging area of research reflects a broader shift in oncology toward recognizing that durable remission may require not only reduction of tumor burden, but also targeting of the biologic mechanisms underlying tumor regeneration.

Clinicians interested in these developments and in the broader evolving field of integrative oncology will have an opportunity to explore these topics further at the 2026 Beljanski Integrative Cancer Conference, to be held June 26–29, 2026, in San Diego, California. The meeting will feature leading experts in integrative and translational oncology discussing advances in cancer stem cell biology, metabolic therapies, immune modulation, and evidence-based natural compounds in cancer care.

Conclusion

The recognition of cancer stem cells as central drivers of recurrence and metastasis has introduced a new paradigm in cancer research. As investigators continue to explore strategies capable of targeting these resilient cellular populations, botanical compounds may emerge as promising adjunctive tools in integrative oncology. Although further clinical validation is required, the prospect of safely suppressing the biologic roots of recurrence represents an important and potentially transformative frontier in breast cancer care.

Disclosure

Sylvie Beljanski is Founder of The Beljanski Foundation Inc., a 501(c)(3) nonprofit organization supporting research in integrative oncology and botanical compounds in cancer care. She has spent over 25 years supporting scientific investigation into natural compounds and cancer biology.

References

1. https://www.bcrf.org/about-breast-cancer/breast-cancer-recurrence/
2. https://www.breastcancer.org/treatment/planning/risk-of-recurrence
3. https://www.beljanski.org/all-cancers/publications/
4. Yu J, Ma Y, Drisko J, Chen Q. Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer. Current Therapeutic Research 2013;75:8–14. doi:10.1016/j.curtheres.2013.04.001
5. Yu J, Chen Q. The plant extract of Pao pereira potentiates carboplatin effects against ovarian cancer. Pharmaceutical Biology 2014;52(1):36–43. doi:10.3109/13880209.2013.808232
6. Yu J, Drisko J, Chen Q. Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira. Oncology Reports 2013;30(1):149–156. doi:10.3892/or.2013.2461
7. Yu J, Chen Q. Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer. Integrative Cancer Therapies 2014;13(3):217–225. doi:10.1177/1534735414532010
8. Yeh, Hsuan-Te et al. Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells. European Journal of Pharmacology vol. 863 (2019): 172658. doi:10.1016/j.ejphar.2019.172658 https://pubmed.ncbi.nlm.nih.gov/31518562/
9. Chen, Ming-Shan et al. Flavopereirine Inhibits Autophagy via the AKT/p38 MAPK Signaling Pathway in MDA-MB-231 Cells. International Journal of Molecular Sciences vol. 21,15 5362. 28 Jul. 2020, doi:10.3390/ijms21155362 https://pubmed.ncbi.nlm.nih.gov/32731544/ 
10. Dong R, Chen P, Yu J, Chen Q. Extract of the medicinal plant Pao pereira inhibits pancreatic cancer stem cells in vitro and in vivo. Integrative Cancer Therapies 2018 Dec;17(4):1204-1215. doi: 10.1177/1534735418786027
11. Dong R, Chen P, Chen Q. Inhibition of pancreatic cancer stem cells by Rauwolfia vomitoria extract Oncology Reports 2018 Dec;40(6):3144-3154. doi:10.3892/or.2018.6713
12. Chen P, Chen Q. Effects of Different Tea Products on the Growth of Cancer Cells. EC Nutrition 14.12 (2019): 01-13 https://www.beljanski.org/wp-content/uploads/2023/05/TEA-GROWTH-K-CELLS-EC-Nutrition-Kansas-2019.pdf
13. Chen P, Wang T, Chen Q. Ginkgo biloba Golden Leaf Extract (GGLE) Inhibits Melanoma Cell Invasion and Angiogenesis Through Inhibition of Angiogenin. Integr Cancer Ther. 2023 Jan-Dec; 22:15347354221134513. doi:10.1177/15347354221134513.